NAD+
Phase 3Small molecule
NAD+ is one of 12 small molecule programs targeting MPR. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in MPR
#DrugCompanyPhaseTrials
1Revia
TevaPhase 3
Lioresal
NovartisPhase 3
Glucophage
EMD SeronoPhase 3
Cytosar
TevaPhase 2
Rapamycin
MMaastricht Radiation Oncology
Phase 3
Glycerin
CCalm Water Therapeutics LLC
Phase 3
Ampyra
MMerz North America, Inc.
Phase 1
NAD+
AAgelessRx
Phase 3
Fragmin
PfizerPreclinical
Agenerase
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NAD+. EMBL-EBI & Wellcome Sanger Institute.
- [4]